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Abstract
Background: The self-controlled case series (SCCS) is a useful design for investigating associations between
outcomes and transient exposures. The SCCS design controls for all fixed covariates, but effect modification can still
occur. This can be evaluated by including interaction terms in the model which, when exponentiated, can be
interpreted as a relative incidence ratio (RIR): the change in relative incidence (RI) for a unit change in an effect
modifier.
Methods: We conducted a scoping review to investigate the use of RIRs in published primary SCCS studies, and
conducted a case-study in one of our own primary SCCS studies to illustrate the use of RIRs within an SCCS analysis
to investigate subgroup effects in the context of comparing whole cell (wcp) and acellular (acp) pertussis vaccines.
Using this case study, we also illustrated the potential utility of RIRs in addressing the healthy vaccinee effect (HVE)
in vaccine safety surveillance studies.
Results: Our scoping review identified 122 primary studies reporting an SCCS analysis. Of these, 24 described the use
of interaction terms to test for effect modification. 21 of 24 studies reported stratum specific RIs, 22 of 24 reported the
p-value for interaction, and less than half (10 of 24) reported the estimate of the interaction term/RIR, the stratum
specific RIs and interaction p-values. Our case-study demonstrated that there was a nearly two-fold greater RI of ER
visits and admissions following wcp vaccination relative to acp vaccination (RIR = 1.82, 95 % CI 1.64–2.01), where RI
estimates in each subgroup were clearly impacted by a strong healthy vaccinee effect.
Conclusions: We demonstrated in our scoping review that calculating RIRs is not a widely utilized strategy. We showed
that calculating RIRs across time periods is useful for the detection of relative changes in adverse event rates that might
otherwise be missed due to the HVE. Many published studies of vaccine-associated adverse events could have missed/
underestimated important safety signals masked by the HVE. With further development, our application of RIRs could be
an important tool to address the HVE, particularly in the context of self-controlled study designs.
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Key messages
 The self-controlled case series design (SCCS) is a
case-only design, and as such the within-subject SCCS
analysis controls for all fixed baseline covariates and
has become a method of choice for studies of adverse
events following vaccination.
 Despite adjustment for baseline covariates, effect
modification can still occur in SCCS analyses and can
be tested by including interaction terms in the SCCS
model. When exponentiated, these interaction terms
can be interpreted as relative incidence ratios (RIR).
 In this paper we present the results of our scoping
review investigating the use of RIRs in published
SCCS analyses, and also a case-study using one of
our primary SCCS studies applying RIRs to investi-
gate comparative subgroup effects, and as a mechanism
to improve the detection and quantification of safety
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signals in the presence of the healthy vaccinee effect
(HVE) in vaccine safety surveillance studies.
 Many published studies of adverse events
immediately following vaccinating using SCCS could
have underestimated or failed to detect important
safety signals by not recognizing and addressing the
impact of the HVE.
Background
Post-marketing surveillance is important for ongoing
evaluation of the safety of vaccines, and is typically
based on observational data, for which conventional
study designs (eg. case-control, cohort) are particularly
vulnerable to confounding. This is because many factors
that are associated with avoidance or delay of vaccin-
ation are also associated with the health outcomes of
interest [1–4].
The self-controlled case series design (SCCS) was
developed to address a number of challenges associated
with studying the association between adverse health
outcomes and transient exposures, such as vaccination,
in observational data. The SCCS is a case-only design
where inference is based on disease cases and their
exposures, in which each individual serves as his or her
own control, implicitly adjusting for all fixed covariates
(eg. sex, socio-economic status) [5–7]. The SCCS is fit
with a conditional Poisson regression model, for which
general use SAS macros and R functions have been
made available by authors of the SCCS methodology in
addition to extensive reference material and examples
(http://statistics.open.ac.uk/sccs) [6].
The fitted SCCS conditional Poisson model provides
estimates of relative incidence (RI) of adverse events,
comparing incidence in exposed periods (eg. immedi-
ately following a vaccination) to unexposed periods,
within individuals. The SCCS has important advantages:
1) it addresses confounding resulting from differences
between the vaccinated and unvaccinated individuals in
non-randomized study settings; 2) traditional cohort and
case-control designs may not be feasible for studying
vaccines with coverage approaching 100 % as it would
be difficult to recruit unvaccinated controls; and 3)
safety surveillance systems typically only collect data for
individuals who reported an adverse event thought to be
related to vaccination.
Despite the built-in control of time-invariant confounders
in an SCCS model, it is possible that effect modification
(interaction) exists such that the magnitude and/or direc-
tion of the RI differs according to one or more (fixed)
covariates (e.g. age, sex, socio-demographic factors, co-
morbidities). Within the framework of an SCCS model it is
possible to address interactions between exposure (e.g.
vaccination) and one or more fixed covariates with respect
to the outcome of interest by including interaction terms
[6]. The exponentiated parameter estimate for the inter-
action term can be interpreted as a “relative incidence ratio”
(RIR) as it is exactly equivalent to the ratio of the RI in one
group compared to the RI in the designated reference
group (if the interacting variable is categorical) or the
change in the relative incidence given a one unit increase in
the covariate (if the interacting variable is continuous). We
have previously published a number of studies comparing
RIs for adverse events following immunization (AEFI)
among important subpopulations using RIRs. We have re-
ported that rates of ER visits and admissions vary according
to: quintiles of birth weight [8], birth order [9], quintiles of
neighborhood income [10], sex [11] and gestational age at
birth (prematurity) [12]. We have also used RIRs to
compare the safety of influenza vaccination in patients with
inflammatory bowel disease to that in healthy controls [13].
Despite its numerous strengths, the SCCS is not immune
to a critical but perhaps under-recognized phenomenon
that can influence the interpretation of an SCCS analysis:
the healthy vaccinee effect (HVE) [14–16]. If an individual
has been ill, recently hospitalized, or otherwise unwell,
vaccination may be deferred by the provider/patient/
parent/guardian until the health of the individual im-
proves. This is especially true for vaccinations in early in-
fancy. For this reason, when observing the health status of
an individual with a completed vaccination, this individual
is more likely to be in a healthy state immediately before
and after their vaccination. The HVE has the effect of
reducing event rates in the immediate pre- and post-
vaccination periods. The impact of the HVE is particularly
evident in studies that utilize non-specific outcome mea-
sures, for example health service utilization (hospital
admissions, ER visits, physician visits), as a metric for
evaluating AEFIs. Figure 1 illustrates the healthy vaccinee
effect for ER visits and admissions relative to date of
vaccination for routine pediatric vaccination at age
6 months in Ontario, Canada.
The impact of the HVE may be much harder to quantify
for less common events such as convulsions, and nearly
impossible for extremely rare events (e.g. encephalitis,
hypotonic hypo-responsive episodes (HHE)). For these
rare and more serious outcomes, the HVE may also not
have enough of an impact to be relevant, but there is not
enough data available to confirm this. It is possible that
studies reporting no increased risk of adverse events
following vaccination may in fact have missed clinically
important safety signals that were distorted by the HVE.
Although the HVE is acknowledged in the literature, its
potential impact on the detection of adverse events in the
first few days following a completed vaccination is not as
well recognized.
Our study sought to: 1) Investigate the use of RIRs
among all published primary SCCS studies through a
comprehensive scoping review, and 2) Present our
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case-study applying relative incidence ratios (RIRs) in
the analysis of one of our own primary SCCS studies
of adverse events following vaccination to investigate
subgroup effects in the context of comparing whole
cell (wcp) and acellular (acp) pertussis vaccines. Using
this case study, we also sought to demonstrate the
potential utility of RIRs in addressing the healthy vac-
cinee effect (HVE) that could mask important safety
signals in many vaccine safety surveillance studies.
Methods
Scoping review of use of RIRs in primary SCCS studies
We searched the PubMed and Scopus databases for all pa-
pers published between January 1st, 1995 and April 30th,
2014 with the keywords “self-controlled case series” OR
“self-controlled risk interval” OR “self-controlled cohort”,
and also all papers that cited any of the main methods
papers describing the SCCS [6, 7, 17–21]. The titles and
abstracts were then reviewed and all studies reporting an
original analysis of observational data using the SCCS
methodology were retained for full review. The full texts
of the retained manuscripts were then reviewed to deter-
mine if interaction tests were performed in the SCCS
model, how they were applied and how the results were
reported, as well as searching the references cited in the
reviewed papers for additional studies that may have been
missed. Detailed information about each study was
extracted and reported in the study results.
Case-study of the application of relative incidence ratios
(RIRs) in an SCCS analysis
The diphtheria, tetanus, acellular pertussis, inactivated
polio and Haemophilus influenzae b (DTaP-IPV-Hib)
component vaccine is given at 2, 4 and 6 months of age in
Ontario, Canada. For component vaccines, adverse reac-
tions typically occur immediately following a vaccination
(0–72 h post-injection) because they contain no live repli-
cating virus. Under these conditions, the risk period over-
laps with the period in which reduced rates of adverse
events are observed due to the HVE. Therefore, when
observing the incidence of adverse events in the most
likely risk period (from 0 to 72 h post-injection for DTaP-
IPV-Hib) versus a control period farther removed from
vaccination, the HVE may mask increased adverse event
risk associated with vaccine administration.
We have previously conducted a study of emergency
room (ER) visits and admissions following DTaP-IPV-Hib
vaccine recommended at ages 2, 4 and 6 months in which
Fig. 1 Frequency of ER visits and hospital admissions in the 3 weeks before and after vaccination (DTaP-IPV-Hib at 6 months of age): Illustration
of the impact of the healthy vaccinee effect: Data from Ontario, Canada [22]. Count = number of combined endpoints of emergency room visit,
hospitalization and death. Days since vaccination = number of days before or after vaccination, day 0 being the day of vaccination
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we found no evidence of increased risk of events in the
first 72 h following vaccination (compared to the control
period: days 9 to 18), but we observed a strong HVE,
which is described by Fig. 1 [22]. In the studies we have
conducted using the SCCS, our implementation of the
design was somewhat atypical in that we defined very
short control periods (e.g. 9 days) and only included ex-
posure time in the post-vaccination period [8–12, 22–24].
Our rationale for the selected control periods was two-
fold. Firstly, when studying vaccinations in early infancy,
background rates of ER visits and hospitalizations change
very rapidly, especially in the first few months following
birth. Therefore, careful age stratification is required to
control for changing background event rates when longer
control intervals are used, which would further complicate
the analysis. Secondly, as vaccinations in first year after
birth are closely spaced (e.g. 2, 4, 6 and 12 months), tight
control intervals were required in order to investigate
associations involving individual vaccinations so that the
control intervals did not overlap with risk periods associ-
ated with subsequent vaccinations. Although we used an
atypical implementation of unexposed control periods in
our case-study, the methods applied in our case study are
broadly applicable to SCCS models in general.
Results
Scoping review of use of RIRs in primary SCCS studies
Our electronic database search returned 334 articles.
Titles and abstracts were reviewed to eliminate dupli-
cates, and to identify those studies that reported an ori-
ginal analysis of observational data using the SCCS
methodology, leaving 122 studies. After retrieval and full
text review of the 122 remaining studies, 24 described
the use of interaction terms in the SCCS model to test
for effect modification. No additional studies were iden-
tified through references listed by the reviewed papers.
Details of the 24 included studies are given in Table 1. For
the final subset of qualifying manuscripts, 10 of 24 studies
reported the estimate of the interaction term/RIR in
addition to the stratum specific relative incidence
estimates and interaction p-values. Twenty-one of 24
studies reported the stratum specific RIs, and 22 of 24
reported the p-value for the test for interaction. Two of 24
studies reported no details of the interaction tests, other
than that they were performed, and did not achieve
statistical significance (Table 1).
Case-study of the application of RIRs in an SCCS analysis
Table 2 presents a comparison of relative incidence of
ER visits and admissions observed among children in
Ontario, Canada in the 3 days following the 2-month
diphtheria-whole-cell-pertussis-tetanus (DPT) vaccin-
ation (risk period) vs. days 9 to 18 (control period). We
compared the RI during the period 1994 to 1996 when
the more reactogenic whole cell pertussis vaccine was
being administered with the RI during the period from
1998 to 2000 when the less reactogenic diphtheria-
tetanus-acellular pertussis vaccine (DTaP) was being
administered. The RI during the whole cell period was
1.08 (95 % CI 1.02–1.15) and the RI during the acellular
period was 0.60 (95 % CI 0.55–0.65). The RIR for the
whole cell versus acellular period was calculated to be
1.82 (95 % CI 1.64–2.01). This provides evidence that the
relative incidence of events was nearly two-fold higher in
the whole-cell versus acellular vaccine usage periods.
Employing the parameter estimates generated from
the fitted conditional Poisson model, the RI in each time
period as well as the RIR comparing the whole cell
versus acellular period can be expressed as:
RI whole cell periodð Þ ¼ exp 1⋅βrisk þ 1⋅βrisk⋅1⋅βperiod
 
¼ 1:08
RI acellular periodð Þ ¼ exp 1⋅βrisk þ 1⋅βrisk⋅0⋅βperiod
 
¼ exp 1⋅βrisk
  ¼ 0:60





where βrisk is the parameter estimate of log (RI) in the
reference group (acellular period) and βperiod is the
parameter estimate of the interaction term of period
(whole cell vs. acellular period) with risk. Since this is a
dichotomous interaction variable, the period variable
would take the value 1 for the whole cell period and 0
for the acellular period. For a categorical interaction
with m categories, period would be a vector of (m-1)
dummy variables indicating subgroup membership, or
period may be a continuous variable. The main effect
terms for the fixed covariates interacting with exposure
cancel out (eg. biological sex does not change between
an individual’s exposed and unexposed periods) leaving
just the interaction terms. A likelihood ratio test is
employed to compare the model with interaction terms
included to the model that excludes these terms. This
tests the hypothesis that the relative incidence of
outcomes with respect to exposure (i.e. vaccination)
depends on the value of the covariate involved in the
interaction [6, 7].
Visual inspection of the daily frequency of events rela-
tive to day of vaccination in both periods strongly sug-
gest that the RI estimates in both the whole cell and
acellular periods were impacted by the healthy vaccinee
effect (Fig. 2). The effect is very similar in the week pre-
ceding vaccination in both the whole cell and the acellu-
lar pertussis periods, but in the days following the whole
Hawken et al. BMC Medical Research Methodology  (2016) 16:126 Page 4 of 9
Table 1 Studies that reported testing for interactions, and/or comparing subgroups in an SCCS modeling context
Study a Exposure Outcomes Interaction Tested Estimates/RIR/int.
p-value reported
Wilson et al. [11] 12 month MMR vaccination ER visits + admissions Sex yes/yes/yes
Kwong et al. [26] Influenza illness and influenza
immunization
Guillain-Barré syndrome Age, sex, month of vaccination yes/no/yes
Benchimol et al.
[13]
Influenza vaccination ER visits + admissions + physician visits
IBD flares
IBD versus healthy controls yes/yes/yes
Wilson et al. [10] 2, 4, 6 (DTaP) and 12 month (MMR)
vaccination
ER visits + admissions SES (Neighborhood income quintiles) yes/yes/yes
Hawken et al. [23] Acellular/whole cell pertussis vaccine ER visits + admissions Whole cell (1994–1996) versus acellular pertussis vaccine (1998–2000) yes/yes/yes
Wilson et al. [12] 2 month vaccination ER visits + admissions Preterm versus full term infants yes/yes/yes
Wilson et al. [8] 2, 4, 6 and 12 month vaccination ER visits + admissions Quintiles of birthweight yes/yes/yes
Connolly-Anderson
et al. [27]
Hemorrhagic fever with renal
syndrome
Acute myocardial infarction and stroke Sex yes/no/yes
Langan et al. [28] Herpes Zoster infection Stroke Antiviral Therapy yes/no/yes
Dodd et al. [29] H1N1 vaccination Guillain-Barré syndrome Age, sex, adjuvanted vs. non-adjuvanted vaccine, concomitant seasonal flu
vaccine
yes/no/yes
Butt et al. [30] Antihypertensives Falls Sex yes/no/yes
Andrews et al. [31] MMR vaccination Thrombocytopenic purpura Country yes/no/yes
Tokars et al. [32] H1N1 and seasonal influenza
vaccination
Guillain-Barré syndrome age, sex, vaccine type, received season flu vaccine, site yes/no/yes
Pariente et al. [33] Antipsychotic use Myocardial infarction Previous history of cardiovascular disease no/no/nob
Warren-Gash et al.
[34]
Influenza vaccination Acute MI Age group, sex, type of infarction, and history of vascular disease yes/no/yes
Tse et al. [35] Influenza vaccination Febrile seizures concomitant 13-valent pneumococcal conjugate vaccine (PCV13), age yes/yes/yes
Gwini et al. [36] Influenza vaccination Acute myocardial infarction Age, sex yes/no/yes
Pattenden et al.
[37]
Heat Exposure Mortality Ozone levels yes/yes/yes
Andrews et al. [38] Acellular pertussis/whole cell pertussis
vaccine
Convulsions, Whole cell period vs. acellular period yes/yes/yes
Douglas et al. [39] Thiazolidinediones Fractures Rosiglitazone versus pioglitazone yes/no/yes
Miller et al. [40] MMR Convulsions and aseptic meningitis Vaccine Manufacturer, Concomitant MCC vaccination vs. separate yes/no/yes
Game et al. [41] Initiation of dialysis Foot ulceration Haemodialysis vs. ambulatory peritoneal dialysis no/no/noa
Miller et al. [42] MMR vaccination Gait Disturbance doses of thimerisol containing vaccines by 4 months, \ mercury exposure
intensity by 6 months
yes/no/yes
Sardinas et al. [43] Oral polio vaccine Intussusception age no/no/yes
aStudies reported above the gray dividing bar are studies published by the authors and their collaborators
















cell vaccinations (1994–1996), there is clearly a spike
in events on the first day following vaccination which
is largely washed out by the HVE (RI 1.08 = 95 % CI
1.02–1.15) but is still statistically significant with p <
0.0001 due to high statistical power. However, in the
acellular period, there appears to be no spike follow-
ing vaccination, but rather in the days following vac-
cination there is an approximate mirror image of the
decrease in event rate seen before vaccination (RI =
0.60, 95 % CI 0.55–0.65). In both periods, the daily
frequency of events is nearly halved by the day before
vaccination with very similar relative incidence for the
week before vaccination compared to the control
period (days 9–18) (Fig. 2).
When we calculated the RIR for the whole cell versus
acellular periods, the similar HVE in both periods is essen-
tially cancelled out and the higher relative incidence of
adverse events associated with the whole cell combination
vaccine becomes clear (RIR = 1.82, 95 % CI 1.64–2.01)
(Fig. 2). This suggests that RIRs provide a useful effect
estimate that can be constructed in such a way to poten-
tially overcome the healthy vaccinee effect to detect safety
signals (or relative changes in safety signals) that might
otherwise be missed.
Discussion
In this manuscript, we presented the results of our scop-
ing review of primary SCCS studies and the use of rela-
tive incidence ratios therein, as well as case-study from
one of our primary SCCS studies providing a worked
example of the utility, strengths and limitations of RIRs
for describing subgroup effects as well as effect modifi-
cation by continuous covariates.
In the context of vaccine safety surveillance, we are
often interested in detecting increases or decreases in
incidence of serious adverse event and changes in
healthcare utilization patterns related to vaccine reac-
tions following introduction of a new vaccine formula-
tion, manufacturer, or other modification. In this case,
interest may be focused on detecting changes in relative
incidence over time or in important subgroups. Using
relative incidence ratios (RIR), the change in relative
incidence across time or physical subgroups of interest
can be estimated and formally tested. For example, if a
different formulation of a vaccine is introduced at a
known point in time, then an SCCS model can be fit,
with common risk and control periods across the entire
population, but an interaction term is then included in
the model, which estimates the RIR comparing the
Table 2 ER Visits and Admissions in the first 72 h following vaccination versus days 9 to 18 for the time period when whole cell





Relative incidence 95 % CI Relative incidence ratio 95 % CI P-valuea
Apr 94–Mar96 (whole-cell) 1323 3663 1.08 1.02–1.15 1.82 1.64–2.01 P < 0.0001
Apr98–Mar00 (acellular) 697 3508 0.60 0.55–0.65 1 (ref) - -
ap-value for interaction of time period (whole cell or acellular periods) with risk
Fig. 2 Emergency room visits and admissions before and after 2-month vaccination for whole cell pertussis combination vaccine (1994–1996)
versus acellular pertussis vaccine (1998–2000). Count = number of combined endpoints of emergency room visit, hospitalization and death.
Days = number of days before or after vaccination, day 0 being the day of vaccination
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period after the new vaccine is introduced versus the
period in which the old formulation was used.
In our case-study we have illustrated how, in some
cases, the HVE can bias the observed relative incidence
of adverse events that occur within the first few days fol-
lowing a vaccination. Calculating the RIR across groups
to be compared (or in our case-study, time periods to be
compared) similarly affected by the HVE would, in ef-
fect, cancel out the HVE and provide a potentially less
biased estimate of the change in RI across the sub-
groups. Therefore, this could present a useful strategy
for overcoming the healthy vaccinee effect, when relative
changes in rates of adverse events across time periods,
jurisdictions or subgroups of vaccines are of primary
interest.
In the SCCS modeling context, RIRs are not afforded
the same protection from confounding as the subgroup
specific RI estimates, which is a potential limitation of
our proposed applications of RIRs. For example, if we
suspect that the relative incidence of adverse events
depends on sex (i.e. females are more susceptible to
adverse events following vaccination than males who are
similarly exposed) we would test this hypothesis by in-
cluding an interaction term between risk period and sex.
This term, if statistically significant, provides evidence
that sex is an effect modifier. However, since we would
now be estimating an interaction effect across levels of a
fixed baseline covariate, this could no longer be consid-
ered a within-individual effect estimate, and hence, any
observed interaction effect could be the result of con-
founding. This issue can be addressed in the same way it
is addressed in other modeling situations, by statistically
controlling for other potential confounders in the SCCS
model in order to assess whether the interaction effect
of interest persists after statistical adjustment. This fur-
ther adjustment is implemented by introducing add-
itional interaction terms for the potential confounder(s)
of interest and then observing whether the parameter
estimate of the target effect modifier changes substan-
tively. Stratified analysis is also a useful strategy to
observe whether the interaction of interest is consistent
across subgroups of known potential confounders of
interest. These remedies afford less reassurance than the
basic SCCS model, which provides main effect estimates
that are implicitly controlled for all known and unknown
fixed covariates. In generating RIR estimates we are lim-
ited to adjusting for known confounders, for which data
are available. Vanderweele and Knol [25] point out that,
if the point of the subgroup analysis is to identify vulner-
able subsets of individuals for possible intervention, then
confounding in interaction effects is of much less
importance. If the aim is to make causal inference with
respect to the source of the interaction, then the
confounding would be important to account for [25].
Conclusions
In this review we have demonstrated the potential utility
of RIRs, which are based upon a test of interaction in
the SCCS conditional Poisson model. We have discussed
the strengths and limitations of RIRs for describing sub-
group effects as well as effect modification by continu-
ous covariates. We have also conducted a scoping review
that demonstrated that very few primary SCCS studies
are making use of RIRs to evaluate relative subgroup
effects.
We have proposed that calculating RIRs across time
periods (year over year for example) is very useful for
detecting relative changes in rates of adverse events,
which could constitute safety signals that might other-
wise be missed due to the HVE. We emphasize many
published studies of adverse events immediately follow-
ing vaccination could have underestimated or failed to
detect potentially important safety signals masked by the
HVE. Our proposed application of RIRs could be an
important tool in future studies to address the HVE.
Further study is needed, including simulation studies
and case studies in real data to assess the impact of
different patterns of healthy vaccinee effect, the impact
of increasing severity of confounding, as well as other
violations of assumptions, on the reliability of inference
using RIRs in post-marketing surveillance using the
SCCS study design.
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